Prognostic values of long noncoding RNA PVT1 in various carcinomas: An updated systematic review and meta‐analysis. (5th September 2018)

• Record Type: Journal Article
• Authors: Xiao, Meizhu; Feng, Ying; Liu, Chongdong; Zhang, Zhenyu
• Is Part Of: Cell proliferation. Volume 51:Number 6(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-09-05
• Subjects: Cell proliferation -- Periodicals; 571.84
• DOI: 10.1111/cpr.12519
• Languages: English
• ISSNs: 0960-7722

Abstract

Abstract: Cancers have been a worldwide health problem with a high mortality rate, but ideal biomarkers are not available to effectively screen and diagnose patients. Currently, an increasing number of long noncoding RNAs have been reported to be abnormally expressed in human carcinomas and play a vital role in tumourigenesis. Plasmacytoma variant translocation 1 (PVT1) is upregulated in various carcinomas, and its overexpression is associated with poor survival in cancer patients. We conduct an updated meta‐analysis to determine its potential in prognosis for tumours. In total, 14 studies comprising 2435 patients were enrolled according to Reporting Recommendations for Tumour Marker Prognostic Studies guidelines. High PVT1 expression indicated poor overall survival (hazard ratio [HR] = 1.98, 95% confidence interval [CI]: 1.62‐2.42, P < 0.00001) and disease‐free survival (HR = 1.63, 95% CI: 1.45‐1.84, P < 0.00001). Additionally, increased PVT1 expression was positively associated with lymphatic node metastasis (odd ratio [OR] = 2.87, 95% CI: 1.66‐4.96, P = 0.0002), distant metastasis (OR = 2.47, 95% CI: 1.74‐3.50, P < 0.00001), advanced tumour‐node‐metastasis stages (OR = 2.59, 95% CI: 1.38‐4.88, P = 0.003). New findings highlight that PVT1 acts as competing RNA to microRNAs to protect mRNAs from miRNAs repression. Therefore, we also discuss PVT1‐related microRNAs and their interaction in tumourigenesis. In conclusion, PVT1 may be a potential biomarker of poor prognosis for patients with different cancer types.